MARKET OVERVIEW- UNITED STATES CELL FREE PROTEIN EXPRESSION MARKET
Cell-free protein expression (CFPE) has become an established tool in recombinant protein synthesis with applications in the high-throughput production of enzymes, antibodies and virus-like particles. It can be described as the process of making desired recombinant proteins in solution without the use of the cell's natural translation machinery. This method is widely used in several applications like, enzyme engineering, protein labelling, protein purification, protein-protein interaction, and high throughput mutant production. It is also used for analysing elements required for protein stability, degradation, and folding. In comparison to cell-based protein expression, cell-free protein expression is time efficient and convenient. It allows the incorporation of non-natural amino acids, and provides enhanced stability and specificity. The cell-free protein expression method is time efficient and convenient, allows the incorporation of non-natural amino acids, and provides enhanced stability and specificity. The growth of the United States Cell Free Protein Expression market is driven by an increasing elderly population, and the rise in prevalence of cancer and infectious diseases across the United States. Furthermore, the growing trend of cell-based research along with rising investments in genomic and proteomic research projects are expected to positively contribute to the growth of the market.
MARKET DRIVERS
The growth of the market is driven by an increasing geriatric population along with a rise in the prevalence of different chronic diseases such as cancer, diabetes, cardiovascular disease, and others. According to the U.S. Census Bureau, more than 56 million adults ages 65 and older live in the United States, accounting for about 16.9% of the nation's population. By 2030, when the last of the baby boomer generation ages into older adulthood, it is projected that there will be more than 73.1 million older adults. An increase in the geriatric population has led to a rise in prevalence of several chronic diseases. According to the CDC, six in ten Americans live with at least one chronic disease, like heart disease and stroke, cancer, or diabetes. According to the U.S. National Center for Health Statistics, about 40 million Americans are limited in their usual activities due to one or more chronic health conditions. Thus, rising cases of chronic disease have created a demand for personalized medicines which can be achieved using cell-free protein expression technique. This is expected to drive the growth of the market over the forecast period. Furthermore, the rise in utilization of cell-free protein expression in the pharmaceutical industry for developing protein-based therapeutics, such as antibodies, antimicrobials, and cytokines, for treating cancer as well as several infectious diseases is expected to positively impact the growth of the market.
MARKET OPPORTUNITIES
The rise in innovative research projects along with technological developments in proteomics are expected to provide lucrative opportunities for key players operating in the market. For instance, in April 2021 Promega announced the opening of the newly constructed R&D facility (Kornberg Center) on its Fitchburg, WI campus. The building will support essential technology and product development in genetic identity, cellular and molecular biology, life science research, scientific applications, clinical diagnostic, and training.
MARKET RESTRAINTS
The cell-free protein expression offers low protein production, making it unsuitable for large industrial applications. This, in turn, is likely to hamper the growth of the market. Additionally, the high cost and short reaction scale of cell-free protein expression techniques are expected to restrain the growth of the market during the estimated time period.
MARKET GROWTH CHALLENGES
The cost of research activities involved in cell-free protein expression is significantly high. It may negatively impact the growth of the market. Also, a lack of effective post-translational modification systems in cell-free protein expression is expected to challenge the market’s growth over the forecast period.
CUMULATIVE GROWTH ANALYSIS
The report provides an in-depth analysis of the United States Cell Free Protein Expression market, market size, and compound annual growth rate (CAGR) for the forecast period of 2023-2029, considering 2022 as the base year. An increase in the prevalence of chronic disease has led to a rise in demand for cell free protein expression technique in various applications, and therefore, the market is expected to witness growth at a specific CAGR from 2023-2029.
UNITED STATES CELL FREE PROTEIN EXPRESSION MARKET SEGMENTAL OVERVIEW
The United States Cell Free Protein Expression market comprises of different market segments like product, application end and users.
UNITED STATES CELL FREE PROTEIN EXPRESSION MARKET BY PRODUCT
By product, the United States Cell Free Protein Expression market includes the key segments like
- E. coli Cell-free Protein Expression System
- Wheat Germ Cell-free Protein Expression System
- Rabbit Reticulocytes Cell-free Protein Expression System
- Insect Cells Cell-free Protein Expression System
- Human Cell-free Protein Expression System
- Others
The E. coli cell-free protein expression system is expected to gain a major share of the market over the forecast period. E. coli cell-free protein expression systems can synthesize a broad variety of proteins, including soluble proteins such as enzymes or reporters, proteins with disulphide bonds such as antibodies and membrane proteins such as channels or transporter
The wheat germ cell-free protein expression system is expected to grow at the fastest rate over the forecast period. This system offers optimal environment for protein synthesis by allocating all metabolic resources to the protein in question, as opposed to basic cellular mechanisms. It is a key factor driving the growth of the segment.
UNITED STATES CELL FREE PROTEIN EXPRESSION MARKET BY APPLICATION
The United States Cell Free Protein Expression market finds key applications in
- Enzyme Engineering
- High Throughput Production
- Protein Labeling
- Protein-Protein Interaction
- Protein Purification
- Other Applications
The enzyme engineering segment is expected to dominate the market over the forecast period. Over the years, cell free protein expression methods have become an established tool for rapid protein synthesis in order to accelerate the discovery of new enzymes and the development of proteins with improved characteristics. This is a key factor driving the growth of the segment.
High throughput production is expected to witness high growth over the forecast period. The cell free protein expression method is widely used in high-throughput functional genomics and proteomics, with significant advantages compared to protein expression in live cells
UNITED STATES CELL FREE PROTEIN EXPRESSION MARKET BY END USERS
The United States Cell Free Protein Expression market has major end users like
- Hospitals and Clinics
- Pharmaceutical and Biotechnology Companies
- Academic and Research Institutes
- Others
The pharmaceutical and biotechnology companies are expected to lead the market over the estimated time period. The expansion of current manufacturing capacities for biopharmaceuticals is stimulating demand for cell-free protein expression products. Also, high investment in biotechnology industries for the launch of innovative solutions is expected to drive the growth of the segment.
Furthermore, the academic and research institutes are expected to witness high growth over the forecast period due to a rise in investments in R&D activities in proteomics and genomics. There is a growing trend of cell-based research in the United States academic institutes.
COVID-19 IMPACT ANALYSIS ON UNITED STATES CELL FREE PROTEIN EXPRESSION MARKET
Axiom MRC provides a 360-degree analysis of micro and macro-economic factors on the United States Cell Free Protein Expression market. In addition, a complete analysis of changes on the United States Cell Free Protein Expression market expenditure, economic and international policies on supply and demand side is provided in this exclusive report. The report also studies the impact of pandemic on the United States economy, international trade, business investments, GDP and marketing strategies of key players present in the market.
The COVID-19 pandemic has had a negative impact on most industries around the world. The healthcare sector has undergone an overhaul during this period. Many pharmaceutical, biotech and medical device manufacturers have suffered both positive and negative impacts from the pandemic. The pandemic had a positive effect on the market. According to the article, "Harnessing proteomics could improve therapeutic approaches to COVID-19," published in November 2020, the development of therapeutic and preventive strategies requires an accurate understanding of proteins' role in the SARS-CoV-2 infection process and progression of COVID-19. This development increased the acceptance of cell-free proteins in the diagnosis of COVID-19. This is expected to contribute to the growth of the market in the upcoming years.
COMPETITIVE LANDSCAPE ANALYSIS
The competitive landscape analysis of the United States Cell Free Protein Expression market is primarily focused on expanding the growth of the cell free protein expression industry in the United States region with new product innovation, business expansion, increasing presence of a range of manufacturers operating in cell free protein expression sector has led the growing demand for the market. Besides, the market offers range of products in different applications to fulfil the required demand of consumer which further contributes healthy growth in the market.
The key players studied in market are
- Merck KGaA
- Cube Biotech GmbH
- CellFree Sciences Co., Ltd.
- Promega Corporation
- Thermo Fisher Scientific
- Creative Biolabs
- Bioneer Corporation
- Jena Bioscience GmbH
- New England Biolabs
- Biotechrabbit GmbH
- LenioBio GmbH
- Moderna Therapeutics
- GeneCopoeia, Inc
- Takara Bio
- Sutro Biopharma Inc
- Otsuka Holding Co. Ltd.
RECENT DEVELOPMENT:
January 2022: Thermo Fisher Scientific Inc. acquired PeproTech for approximately USD 1.85 billion. Through this acquisition, PeproTech's recombinant proteins portfolio will complement Thermo Fisher's cell culture media products and further enable Thermo Fisher to provide its customers significant benefits through an integrated offering.
September 2021: Sutro Biopharma extended the cytokine derivative research program in partnership with Merck. Under the terms of this agreement, Merck and Sutro are performing preclinical R&D of cytokine derivatives using Sutro's exclusive site-specific conjugation and cell-free protein synthesis platforms, Xpress CF+ and XpressCF.
